Bioprinting in Tissue Repair and Its ENT Applications
Vlad T., Mituletu M., Flangea C., Marina CD., Caraba MN., Balica NC.
Narrative Review, published in Polymers (Basel) (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Polymers (Basel) (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41977569
- PMCID
- PMC13075192
- DOI
- 10.3390/polym18070821
Abstract (original English)
Biotissues represent a new technology in tissue regeneration in otolaryngology. Various biomaterials functioning in different combinations are used as bioinks for 3D bioprinting of tissues/tissue fragments. The scaffolds can be populated with several cell categories, each offering distinct advantages and disadvantages, depending on the targeted pathology. Results from in vitro and in vivo studies on animal models are promising, with superior therapeutic potential. The combination of these elements provides promising results, enabling their potential application in personalized medicine. Based on these findings, their application in ENT (ear, nose, and throat) pathology is starting to gain traction. Despite being an emerging field, 3D/4D bioprinting in otolaryngology is rapidly evolving, increasingly replacing conventional inert materials with more sophisticated, bio-integrated alternatives. These alternatives are based on novel bioink formulation involving cells capable of proliferating and integrating the new neo-fragment organ into the host's endogenous tissues. In this context, this review outlines novel applications that could enhance traditional procedures in ENT reconstructive medicine. Furthermore, biomimetic scaffolds for otolaryngology can be tailored to address factors influencing implant fate during the procedure and in the early and late postoperative periods.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.